InsiderTrades

Form 4 for IONS IONIS PHARMACEUTICALS INC

Accepted 2026-07-09 19:26:31 ET · period of report 2026-07-07 · accession 0000874015-26-000239 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DT 2026-07-09 19:26 2026-07-07 IONS BENNETT C FRANK EVP, CSO S - Sale $83.58 -5,536 75.0K -7% -$462.7K
DTI 2026-07-09 19:26 2026-07-07 IONS BENNETT C FRANK EVP, CSO J - Other $0.00 +15.0K 15.0K New $0
DTI 2026-07-09 19:26 2026-07-07 IONS BENNETT C FRANK EVP, CSO S - Sale $85.46 -15.0K 0 -100% -$1.28M
DT 2026-07-09 19:26 2026-07-07 IONS BENNETT C FRANK EVP, CSO J - Other $0.00 -15.0K 12.1K -55% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-07-07 S D 5,536 $83.58 75,018 D — — (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.070 to $84.065 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
2 Common Common Stock 2026-07-07 J A 15,000 $0.00 15,000 I by Trust — — (F3) Represents a transfer of 15,000 shares of common stock from direct ownership to indirect ownership held by the Clarence Frank Bennett TTEE Bennett Living Trust Dated 3/12/2008, of which the reporting person is the co-trustee with spouse.
3 Common Common Stock 2026-07-07 S D 15,000 $85.46 0 I by Trust — — (F1) Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 31, 2026. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.015 to $85.730 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
4 Derivative Restricted Stock Unit 2026-07-07 J D 15,000 $0.00 12,109 D $0.00 · — to — 15,000 Common Stock (F5) Restricted Stock Unit vested on January 15, 2026. Upon vesting, the restricted stock unit was paid out in whole shares of Ionis common stock. (F5) Restricted Stock Unit vested on January 15, 2026. Upon vesting, the restricted stock unit was paid out in whole shares of Ionis common stock.